Cryptome to collaborate with IMB
Tuesday, 07 December, 2004
Cryptome (ASX: CRP) has signed a memorandum of understanding with the Institute of Molecular Bioscience (IMB) to collaborate on the identification of cardiovascular therapeutics.
The company will combine the high throughput screening capabilities of Cryptomics platform technology, which is based on the identification of small protein fragments with previously undiscovered therapeutic activity, with the IMB's compound libraries, to identify compounds with therapeutic potential in the treatment of cardiovascular disease.
"Bringing together IMB's novel compound libraries and our screening capabilities will make a powerful combination in a most important clinical area," said Cryptome's acting CEO Prof Mathew Vadas.
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
Breast augmentation procedure uses 3D-printed scaffolds
3D-printed scaffold technology from medtech company BellaSeno has been used in a primary breast...
Victoria detects H5N1 avian influenza strain
It follows disease confirmation in seabirds in WA, SA, NSW and Qld and the national decision that...
